CVE:AQSAequus Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aequus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$0.10 0.00 (-4.55 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's RangeC$0.10Now: C$0.11▼C$0.1150-Day RangeC$0.07MA: C$0.08▼C$0.1152-Week RangeC$0.07Now: C$0.11▼C$0.18Volume257,500 shsAverage Volume90,078 shsMarket CapitalizationC$11.73 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileChartCompetitorsEarningsHeadlinesSocial Media Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Zepto, a precision pulse capsulotomy system that provides anterior lens capsulotomies during cataract surgeries; and Topiramate and Oxcarbazepine extended-release tablets for the treatment of epilepsy. Its development stage product candidates include AQS1301, a transdermal formulation of aripiprazole for the treatment of bipolar I disorders, schizophrenia, and irritability associated with autistic disorders, as well as depressive disorders; AQS1303, a transdermal pyridoxine/ doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304 to treat neurological disorders. The company has a collaboration agreement with Scientus Pharma Inc. for the development and commercial supply of specific cannabinoid extracts; and licensing agreement with Supernus Pharmaceuticals, Inc. for the development and commercialization of products for the treatment of central nervous system disorders. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Aequus Pharmaceuticals. Previous Next 2.6 Community Rank Outperform VotesAequus Pharmaceuticals has received 63 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAequus Pharmaceuticals has received 60 “underperform” votes. (Add your “underperform” vote.)Community SentimentAequus Pharmaceuticals has received 51.22% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aequus Pharmaceuticals and other stocks. Vote “Outperform” if you believe AQS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AQS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAequus Pharmaceuticals does not currently pay a dividend.Dividend GrowthAequus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aequus Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Aequus Pharmaceuticals is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aequus Pharmaceuticals is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.52 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolCVE:AQS Previous Symbol CUSIPN/A CIKN/A Webwww.aequuspharma.ca Phone+1-604-3367906Debt Debt-to-Equity Ratio1,096.63 Current Ratio1.71 Quick Ratio1.61Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$1.88 million Price / Sales6.23 Cash FlowC$0.01 per share Price / Cash Flow18.75 Book ValueC($0.02) per share Price / Book-7.00Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees10 Outstanding Shares111,688,000Market CapC$11.73 million Next Earnings Date8/25/2020 (Estimated) OptionableNot Optionable C$0.10 0.00 (-4.55 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AQS News and Ratings via Email Sign-up to receive the latest news and ratings for AQS and its competitors with MarketBeat's FREE daily newsletter. Aequus Pharmaceuticals (CVE:AQS) Frequently Asked Questions How has Aequus Pharmaceuticals' stock been impacted by COVID-19? Aequus Pharmaceuticals' stock was trading at C$0.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AQS shares have decreased by 4.5% and is now trading at C$0.11. View which stocks have been most impacted by COVID-19. When is Aequus Pharmaceuticals' next earnings date? Aequus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 25th 2020. View our earnings forecast for Aequus Pharmaceuticals. How were Aequus Pharmaceuticals' earnings last quarter? Aequus Pharmaceuticals Inc (CVE:AQS) posted its quarterly earnings data on Monday, June, 1st. The company reported ($0.01) EPS for the quarter. The company had revenue of $0.58 million for the quarter. View Aequus Pharmaceuticals' earnings history. Has Aequus Pharmaceuticals been receiving favorable news coverage? News stories about AQS stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aequus Pharmaceuticals earned a coverage optimism score of -1.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Aequus Pharmaceuticals. Who are some of Aequus Pharmaceuticals' key competitors? Some companies that are related to Aequus Pharmaceuticals include MGC Pharmaceuticals (MXC), Harvest One Cannabis (HVT), Eve & Co Inc (EVE), Evgen Pharma (EVG), SugarBud Craft Growers (SUGR), NeutriSci International (NU), Cannpal Animal Therapeutics (CP1), Lattice Biologics (LBL), 1933 Industries (TGIF), Abacus Health Products (ABAHF), Acreage (ACRGF), Alliance Growers (ACG), Applied Biosciences (APPB), Ayr Strategies (AYRSF) and Biome Grow (BIO). View all competitors. What other stocks do shareholders of Aequus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aequus Pharmaceuticals investors own include Growlife (PHOT), Terra Tech (TRTC), Acorn Energy (ACFN), CROWN CASTLE IN/SH SH (CCI), Charlotte's Web (CWBHF), Supreme Cannabis (FIRE), LiCo Energy Metals (LIC), Marijuana Company Of America (MCOA), Rogers (ROG) and Aurora Cannabis (ACB). Who are Aequus Pharmaceuticals' key executives? Aequus Pharmaceuticals' management team includes the following people: Mr. Douglas Glen Janzen, Chairman, CEO & Pres (Age 50)Ms. Ann Fehr CGA, CPA, Chief Financial Officer (Age 50)Ms. Anne Michelle Stevens BSc, MHA, COO, Corp. Sec. & Director (Age 38)Mr. Ian Richard Ball, Chief Commercial OfficerDr. Donald Alan McAfee, Chief Scientific Officer (Age 77) What is Aequus Pharmaceuticals' stock symbol? Aequus Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "AQS." How do I buy shares of Aequus Pharmaceuticals? Shares of AQS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Aequus Pharmaceuticals' stock price today? One share of AQS stock can currently be purchased for approximately C$0.11. How big of a company is Aequus Pharmaceuticals? Aequus Pharmaceuticals has a market capitalization of C$11.73 million and generates C$1.88 million in revenue each year. Aequus Pharmaceuticals employs 10 workers across the globe. What is Aequus Pharmaceuticals' official website? The official website for Aequus Pharmaceuticals is www.aequuspharma.ca. How can I contact Aequus Pharmaceuticals? Aequus Pharmaceuticals' mailing address is 2820-200 Granville St, VANCOUVER, BC V6C 1S4, Canada. The company can be reached via phone at +1-604-3367906. This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
